Related Experiment Video
Updated: Jun 27, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
Gynecomastia: a rare adverse effect of isoniazid
Nelson Morrone1, Nelson Morrone Junior, Alessandra Garcia Braz
1Dispensário do Ipiranga, Ação Comunitária de Saúde. nmorrone@uol.com.br
Abstract:
We report the case of a patient who twice developed gynecomastia following tuberculosis treatment. An 18-year-old male developed painful bilateral gynecomastia after three months of treatment with the isoniazid-rifampin-pyrazinamide regimen. Partial resolution of gynecomastia was achieved at the end of treatment. The patient was retreated with the same regimen eight years later, and gynecomastia recurred after six months of treatment. Hormone levels were normal, and a mammogram revealed bilateral gynecomastia. The isoniazid was discontinued, and the gynecomastia was partially resolved by the end of treatment. Four years later, gynecomastia was not detected. We conclude that isoniazid-related gynecomastia completely resolves when the medication is discontinued. Therefore, pharmacological and surgical treatment should be avoided.
Related Concept Videos
Cirrhosis I: Introduction
Drugs for Treatment of Constipation-Predominant IBS
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug toxicity: Idiosyncratic Reactions
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment